Smith & Nephew SNATS Inc. Common Stock (SNN)
Stock · NYSE · Health Care
$29.06as of 10/16/2026
Price chart
Active signals
SNN Signal Track Record
How signals performed across all stocks →What SNN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | -0.4% | 49% | September 1, 2026 |
| Bollinger Band BreakoutActive now | 23 | +0.6% | 57% | July 28, 2026 |
| Bollinger Band Breakdown | 19 | -0.3% | 47% | September 8, 2026 |
| 200-Day Moving Average TouchActive now | 17 | +1.1% | 65% | July 28, 2026 |
| Any 20-session window (baseline) | +0.3% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SNN
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities…
- Sector
- Health Care
- Industry
- Industrial Specialties
- Employees
- 17,000
- Website
- www.smith-nephew.com/
Fundamentals
- 1-day range
- $28.94$29.38
- Market cap
- $12.61B
- P/E (trailing)
- 18.34
- P/E (forward)
- 12.07
- EPS (trailing)
- $0.74
- Dividend yield
- 2.95%
- Beta
- 1.02
- Avg. volume
- 1.58M
- Ex-dividend date
- October 2, 2026
- Dividend pay date
- November 6, 2026
Forecasts
5 analyst ratings
Smith & Nephew SNATS Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SNNSmith & Nephew SNATS Inc. Common Stock$29.06▼ 0.10%Market cap $12.61BP/E 18.34$980.4$1,427
- ALGNAlign Technology Inc. Common Stock$147.31▼ 1.36%Market cap $12.11BP/E 25.36$126.33$200.44
- AITApplied Industrial Technologies Inc. Common Stock$330.48▼ 1.00%Market cap $13.27BP/E 29.52$238.72$374.8
- MASMasco Corporation Common Stock$72.87▲ 0.40%Market cap $14.88BP/E 15.88$58.16$83.64
- POOLPool Corporation Common Stock$172.57▲ 2.04%Market cap $7.31BP/E 14.90$152.7$305.63
- ZBHZimmer Biomet Holdings Inc. Common Stock$94.98▲ 0.64%Market cap $18.80BP/E 22.28$79.12$106.88
- MTRNMaterion Corporation$245.44▼ 2.66%Market cap $5.79BP/E 56.96$109.61$324.99
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SNN Smith & Nephew SNATS Inc. Common Stock | $12.61B | 18.34 | $29.06 | ▼ 0.10% | $980.4$1,427 |
| ALGN Align Technology Inc. Common Stock | $12.11B | 25.36 | $147.31 | ▼ 1.36% | $126.33$200.44 |
| AIT Applied Industrial Technologies Inc. Common Stock | $13.27B | 29.52 | $330.48 | ▼ 1.00% | $238.72$374.8 |
| MAS Masco Corporation Common Stock | $14.88B | 15.88 | $72.87 | ▲ 0.40% | $58.16$83.64 |
| POOL Pool Corporation Common Stock | $7.31B | 14.90 | $172.57 | ▲ 2.04% | $152.7$305.63 |
| ZBH Zimmer Biomet Holdings Inc. Common Stock | $18.80B | 22.28 | $94.98 | ▲ 0.64% | $79.12$106.88 |
| MTRN Materion Corporation | $5.79B | 56.96 | $245.44 | ▼ 2.66% | $109.61$324.99 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Smith+Nephew Launches CARTIHEAL Implant Across Key European MarketsYahoo · 10/8/2026
- Howden Joinery Group Plus 2 British Undervalued Stocks To WatchYahoo · 10/7/2026
- Smith & Nephew Launches CartiHeal Cartilage Repair Implant in EuropeYahoo · 10/6/2026
- Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo.Yahoo · 10/6/2026
- Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de PortugalYahoo · 10/6/2026
- Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in PortugalYahoo · 10/6/2026
- Owens & Minor Names Carrie Childress Its First Chief Marketing Officer in Company HistoryYahoo · 10/1/2026
- GS adds four European stocks to conviction list as earnings catalysts emergeYahoo · 10/1/2026
- Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yieldsbenzinga · 9/8/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 31.63M
- Total value held
- $967.35M
- Institutional holders
- 274
- Unknown3.24M
- Unknown2.46M
- Unknown2.24M
- Unknown1.77M
- Unknown1.39M
- Unknown1.39M
- Unknown1.34M
- Unknown1.24M
- Unknown1.05M
- Unknown953.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Smith & Nephew launches EVOS PELVIC System
Smith & Nephew has introduced its new EVOS PELVIC System, a device aimed at improving trauma care. The launch comes as the sports rehabilitation equipment market is expected to grow from $2.05 billion in 2026 to $6.84 billion by 2030, highlighting demand for advanced recovery solutions. Additionally, the company was added to Goldman Sachs’ European conviction list, suggesting analysts view it as a potential earnings catalyst. These developments suggest renewed focus on product innovation and market expansion for the firm.
Smith & Nephew launches EVOS PELVIC System. Smith & Nephew has introduced its new EVOS PELVIC System, a device aimed at improving trauma care. The launch comes as the sports rehabilitation equipment market is expected to grow from $2.05 billion in 2026 to $6.84 billion by 2030, highlighting demand for advanced recovery solutions. Additionally, the company was added to Goldman Sachs’ European conviction list, suggesting analysts view it as a potential earnings catalyst. These developments suggest renewed focus on product innovation and market expansion for the firm.